StockUS listing USINNMFPINKHealthcareProfitless Growth

Amplia Therapeutics Limited(INNMF) Stock Analysis | Healthcare

USD --+0.00%
Reward57Moderate
Risk51Moderate
75%Data
Thin -158% profit margin · Revenue growing 87% YoY
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 56.93M
Reward Ratingⓘ57 Moderate reward assessment · 75% data coverage
Top 50% of stocksView factors
Risk Ratingⓘ51 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on INNMF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Amplia Therapeutics Limited?

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.

AI Brief Pro

The brief on Amplia Therapeutics Limited

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Amplia Therapeutics Limited?

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 56.93M.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (57)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.812
Insider Activity
12M windowNo data
No insider activity data available for this ticker.